<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82886">
  <stage>Registered</stage>
  <submitdate>9/06/2008</submitdate>
  <approvaldate>13/06/2008</approvaldate>
  <actrnumber>ACTRN12608000295347</actrnumber>
  <trial_identification>
    <studytitle>Targeting of treatment of the patent ductus arteriosus using early echocardiography</studytitle>
    <scientifictitle>Response of premature infants born before 29 weeks gestation to early targeted treatment with indomethacin vs placebo in terms of the combined outcome of mortality/abnormal head ultrasound at nursery discharge.</scientifictitle>
    <utrn />
    <trialacronym>DETECT</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Patent ductus arteriosus</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Indomethacin (0.2mg loading dose intravenously followed by two doses of 0.1mg/kg at 24 hour intervals intravenously) given in first 12 hours of life in high risk premature infants with patent ductus arteriosus failing to constrict naturally as defined by an echocardiogram.</interventions>
    <comparator>Echocardiogram in first 12 hours of life - no treatment if ductus constricted, 3 doses of normal saline placebo IV (0.1mls/kg followed by two doses of 0.05mls/kg) if ductus defined as large on echocardiogram.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Early detection / Screening</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Combined death and abnormal cranial ultrasound</outcome>
      <timepoint>Nursery discharge</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Chronic lung disease as measured by need for any supplemental oxygen or pressure support</outcome>
      <timepoint>36 weeks corrected post menstrual age</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Infants born &lt; 29 weeks gestational age
Infants &lt; 12 hours old
Echocardiogram to assess ductal size able to be performed</inclusivecriteria>
    <inclusiveminage>3</inclusiveminage>
    <inclusiveminagetype>Hours</inclusiveminagetype>
    <inclusivemaxage>12</inclusivemaxage>
    <inclusivemaxagetype>Hours</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1] Intraventricular haemorrhage grade 3  4 at time of initial scan.
2] Baby is clinically unstable and not expected to survive.
3] Congenital anomalies predicted to influence neurodevelopmental outcome
4] Structural heart disease
5] R-&gt;L shunt - infants with near systemic or suprasystemic pulmonary pressure who may benefit from some RV pressure relief  R&gt;L ductal flow for &gt;33% of cardiac cycle. Rescan in same 12 hour time frame.
6] Contraindication to use of indomethacin or ibuprofen (Platelet count &lt;50,000, Creatinine &gt;120 micromol/L, use of NSAID antenatally)
7] Unlikely to be able to commence first dose of treatment by 12 hours of age
8] Consent not given</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>A permutated block randomisation method was used to develop a randomisation table for each gestational age group. Pharmacists not involved with the care of the infant allocated sequential study numbers to masked syringes of either placebo or indomethacin. After study enrolment the next sequential numbered syringe for that block is used for treatment.</concealment>
    <sequence>Random number sequence was generated by permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>370</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2065</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Martin Kluckow</primarysponsorname>
    <primarysponsoraddress>Royal North Shore Hospital
Pacific Highway
St Leonards</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Royal North Shore Hospital</sponsorname>
      <sponsoraddress>Pacific Highway
St Leonards</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Andy Gill
Neonatal Unit
King Edward Memorial Hospital</othercollaboratorname>
      <othercollaboratoraddress>374 Bagot Road
Subiaco
Perth</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Nick Evans
Neonatal Unit
Royal Prince Alfred Hospital</othercollaboratorname>
      <othercollaboratoraddress>Missenden Road
Camperdown</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Harbour Northern Sydney Central Coast</ethicname>
      <ethicaddress>Research Office
Level 4, Vindin House
Royal North Shore Hospital</ethicaddress>
      <ethicapprovaldate>17/04/2008</ethicapprovaldate>
      <hrec>0802-012M</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Martin Kluckow</name>
      <address>Royal North Shore Hospital
St Leonards</address>
      <phone>+61 2 99267509</phone>
      <fax />
      <email>mkluckow@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Martin Kluckow</name>
      <address>Royal North Shore Hospital
St Leonards</address>
      <phone>+61 2 99267509</phone>
      <fax />
      <email>mkluckow@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>